Cargando…

Suboptimal primary and secondary cardiovascular disease prevention in HIV-positive individuals on antiretroviral therapy

BACKGROUND: We aimed to identify the prevalence of cardiovascular risk factors, and investigate preventive cardiovascular medication use and achievement of targets as per Dutch cardiovascular risk management guidelines among human immunodeficiency virus (HIV)-positive and HIV-negative individuals. D...

Descripción completa

Detalles Bibliográficos
Autores principales: van Zoest, Rosan A, van der Valk, Marc, Wit, Ferdinand W, Vaartjes, Ilonca, Kooij, Katherine W, Hovius, Joppe W, Prins, Maria, Reiss, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548068/
https://www.ncbi.nlm.nih.gov/pubmed/28578613
http://dx.doi.org/10.1177/2047487317714350
_version_ 1783255785121251328
author van Zoest, Rosan A
van der Valk, Marc
Wit, Ferdinand W
Vaartjes, Ilonca
Kooij, Katherine W
Hovius, Joppe W
Prins, Maria
Reiss, Peter
author_facet van Zoest, Rosan A
van der Valk, Marc
Wit, Ferdinand W
Vaartjes, Ilonca
Kooij, Katherine W
Hovius, Joppe W
Prins, Maria
Reiss, Peter
author_sort van Zoest, Rosan A
collection PubMed
description BACKGROUND: We aimed to identify the prevalence of cardiovascular risk factors, and investigate preventive cardiovascular medication use and achievement of targets as per Dutch cardiovascular risk management guidelines among human immunodeficiency virus (HIV)-positive and HIV-negative individuals. DESIGN: The design was a cross-sectional analysis within an ongoing cohort study. METHODS: Data on medication use and cardiovascular disease prevalence were available for 528 HIV-positive and 521 HIV-negative participants. We identified cardiovascular risk factors and applied cardiovascular risk management guidelines, mainly focusing on individuals eligible for (a) primary prevention because of high a priori cardiovascular risk, or for (b) secondary prevention. RESULTS: One hundred and three (20%) HIV-positive and 77 (15%) HIV-negative participants were classified as having high cardiovascular risk; 53 (10%) HIV-positive and 27 (5%) HIV-negative participants were eligible for secondary prevention. Of HIV-positive individuals 57% at high cardiovascular risk and 42% of HIV-positive individuals eligible for secondary prevention had systolic blood pressures above guideline-recommended thresholds. Cholesterol levels were above guideline-recommended thresholds in 81% of HIV-positive individuals at high cardiovascular risk and 57% of HIV-positive individuals eligible for secondary prevention. No statistically significant differences were observed between HIV-positive and HIV-negative participants regarding achievement of targets, except for glycaemic control (glycated haemoglobin ≤ 53 mmol/mol) among individuals using diabetes medication (90% vs 50%, p = 0.017) and antiplatelet/anticoagulant use for secondary prevention (85% vs 63%, p = 0.045), which were both superior among HIV-positive participants. CONCLUSIONS: Cardiovascular risk management is suboptimal in both HIV-positive and HIV-negative individuals and should be improved.
format Online
Article
Text
id pubmed-5548068
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-55480682017-08-23 Suboptimal primary and secondary cardiovascular disease prevention in HIV-positive individuals on antiretroviral therapy van Zoest, Rosan A van der Valk, Marc Wit, Ferdinand W Vaartjes, Ilonca Kooij, Katherine W Hovius, Joppe W Prins, Maria Reiss, Peter Eur J Prev Cardiol CVD Risk Factors BACKGROUND: We aimed to identify the prevalence of cardiovascular risk factors, and investigate preventive cardiovascular medication use and achievement of targets as per Dutch cardiovascular risk management guidelines among human immunodeficiency virus (HIV)-positive and HIV-negative individuals. DESIGN: The design was a cross-sectional analysis within an ongoing cohort study. METHODS: Data on medication use and cardiovascular disease prevalence were available for 528 HIV-positive and 521 HIV-negative participants. We identified cardiovascular risk factors and applied cardiovascular risk management guidelines, mainly focusing on individuals eligible for (a) primary prevention because of high a priori cardiovascular risk, or for (b) secondary prevention. RESULTS: One hundred and three (20%) HIV-positive and 77 (15%) HIV-negative participants were classified as having high cardiovascular risk; 53 (10%) HIV-positive and 27 (5%) HIV-negative participants were eligible for secondary prevention. Of HIV-positive individuals 57% at high cardiovascular risk and 42% of HIV-positive individuals eligible for secondary prevention had systolic blood pressures above guideline-recommended thresholds. Cholesterol levels were above guideline-recommended thresholds in 81% of HIV-positive individuals at high cardiovascular risk and 57% of HIV-positive individuals eligible for secondary prevention. No statistically significant differences were observed between HIV-positive and HIV-negative participants regarding achievement of targets, except for glycaemic control (glycated haemoglobin ≤ 53 mmol/mol) among individuals using diabetes medication (90% vs 50%, p = 0.017) and antiplatelet/anticoagulant use for secondary prevention (85% vs 63%, p = 0.045), which were both superior among HIV-positive participants. CONCLUSIONS: Cardiovascular risk management is suboptimal in both HIV-positive and HIV-negative individuals and should be improved. SAGE Publications 2017-06-05 2017-08 /pmc/articles/PMC5548068/ /pubmed/28578613 http://dx.doi.org/10.1177/2047487317714350 Text en © The European Society of Cardiology 2017 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle CVD Risk Factors
van Zoest, Rosan A
van der Valk, Marc
Wit, Ferdinand W
Vaartjes, Ilonca
Kooij, Katherine W
Hovius, Joppe W
Prins, Maria
Reiss, Peter
Suboptimal primary and secondary cardiovascular disease prevention in HIV-positive individuals on antiretroviral therapy
title Suboptimal primary and secondary cardiovascular disease prevention in HIV-positive individuals on antiretroviral therapy
title_full Suboptimal primary and secondary cardiovascular disease prevention in HIV-positive individuals on antiretroviral therapy
title_fullStr Suboptimal primary and secondary cardiovascular disease prevention in HIV-positive individuals on antiretroviral therapy
title_full_unstemmed Suboptimal primary and secondary cardiovascular disease prevention in HIV-positive individuals on antiretroviral therapy
title_short Suboptimal primary and secondary cardiovascular disease prevention in HIV-positive individuals on antiretroviral therapy
title_sort suboptimal primary and secondary cardiovascular disease prevention in hiv-positive individuals on antiretroviral therapy
topic CVD Risk Factors
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548068/
https://www.ncbi.nlm.nih.gov/pubmed/28578613
http://dx.doi.org/10.1177/2047487317714350
work_keys_str_mv AT vanzoestrosana suboptimalprimaryandsecondarycardiovasculardiseasepreventioninhivpositiveindividualsonantiretroviraltherapy
AT vandervalkmarc suboptimalprimaryandsecondarycardiovasculardiseasepreventioninhivpositiveindividualsonantiretroviraltherapy
AT witferdinandw suboptimalprimaryandsecondarycardiovasculardiseasepreventioninhivpositiveindividualsonantiretroviraltherapy
AT vaartjesilonca suboptimalprimaryandsecondarycardiovasculardiseasepreventioninhivpositiveindividualsonantiretroviraltherapy
AT kooijkatherinew suboptimalprimaryandsecondarycardiovasculardiseasepreventioninhivpositiveindividualsonantiretroviraltherapy
AT hoviusjoppew suboptimalprimaryandsecondarycardiovasculardiseasepreventioninhivpositiveindividualsonantiretroviraltherapy
AT prinsmaria suboptimalprimaryandsecondarycardiovasculardiseasepreventioninhivpositiveindividualsonantiretroviraltherapy
AT reisspeter suboptimalprimaryandsecondarycardiovasculardiseasepreventioninhivpositiveindividualsonantiretroviraltherapy